<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843154</url>
  </required_header>
  <id_info>
    <org_study_id>CANc-CHF14-TIF</org_study_id>
    <secondary_id>2005-001306-87</secondary_id>
    <secondary_id>U1111-1114-0042</secondary_id>
    <nct_id>NCT00843154</nct_id>
  </id_info>
  <brief_title>Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure</brief_title>
  <acronym>CANDHEART</acronym>
  <official_title>Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Candesartan, once daily (QD), added&#xD;
      to ongoing chronic heart disease therapy in measuring brain natriuretic peptide in patients&#xD;
      with chronic heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic heart failure is a significant and increasing cause of morbidity and mortality,&#xD;
      accounting for a current yearly prevalence of 5 million and a 5-year survival near 50% in the&#xD;
      US. In addition, chronic heart failure is still the fourth cause of hospitalization in the US&#xD;
      and in Western countries, and it is the leading cause of hospitalization in patients aged&#xD;
      over 65.&#xD;
&#xD;
      Newer pharmacological agents and non pharmacological therapeutic tools have been increasingly&#xD;
      introduced to improve the outcomes in patients with chronic heart failure. In the past two&#xD;
      decades, several large randomized controlled clinical trials have revolutionized the&#xD;
      management and prognosis of patients with chronic heart failure. The recommended drug&#xD;
      treatment for decreasing mortality and morbidity in chronic heart failure is based on&#xD;
      angiotensin converting enzyme-inhibitors, beta-blockers and aldosterone antagonists (limited&#xD;
      to most severe patients), as detailed in the latest European Society of Cardiology&#xD;
      guidelines. The use of digitalis and diuretics still has a role.&#xD;
&#xD;
      Orally active angiotensin II type I receptor blockers represent a new class of agents that&#xD;
      offer an alternative method of the renin-angiotensin system blockade. Their effects on&#xD;
      hemodynamics, neuroendocrine activity and exercise tolerance in patients with chronic heart&#xD;
      failure can be considered as similar to that exhibited by angiotensin converting enzyme&#xD;
      -inhibitors, but it still remains to be fully elucidated whether angiotensin II type I&#xD;
      receptor blockers can offer advantage in efficacy, other than in safety, compared to&#xD;
      angiotensin converting enzyme -inhibitors.&#xD;
&#xD;
      Brain Natriuretic Peptide is strongly related to the severity and to the increase of&#xD;
      cardiovascular events in patients with chronic heart failure. Recent data show that&#xD;
      angiotensin II receptor blockers can reduce the levels of Brain Natriuretic Peptide, though&#xD;
      no data is available in patients with preserved left ventricular systolic function.&#xD;
&#xD;
      Candesartan is a selective angiotensin II type I receptor blocker, and this study will&#xD;
      evaluate the effects of the maximum tolerated dose of Candesartan added to ongoing standard&#xD;
      therapy while measuring changes in brain natriuretic peptide biomarker used in the assessment&#xD;
      of chronic heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment&#xD;
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Brain Natriuretic Peptide</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Brain Natriuretic Peptide</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Aldosterone, Pentraxin-3 and C-Reactive Protein</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of New York Heart Association class</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Left Ventricular Ejection Fraction, Left Ventricular Internal Diastolic Diameter, E wave peak velocity/A wave peak velocity, deceleration time of E wave, atrial dimensions, blood pressure and heart rate</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of active treatment and discontinuation rate</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>Week 48 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">571</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Candesartan QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chronic heart disease therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan and standard chronic heart disease therapy</intervention_name>
    <description>Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.</description>
    <arm_group_label>Candesartan QD</arm_group_label>
    <other_name>Blopress</other_name>
    <other_name>Amias</other_name>
    <other_name>Kenzen</other_name>
    <other_name>Atacand</other_name>
    <other_name>Blopressid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chronic heart disease therapy</intervention_name>
    <description>Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.</description>
    <arm_group_label>Standard chronic heart disease therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Stable, symptomatic New York Heart Association II-IV Chronic Heart Failure with Left&#xD;
             Ventricular Ejection Fraction less than or greater than or greater than or equal to&#xD;
             40% treated with standard therapy including Angiotensin Converting Enzyme-inhibitors&#xD;
             and/or beta-blockers. Patients with Left Ventricular Ejection Fraction greater than or&#xD;
             equal to 40% had to be hospitalized for cardiovascular events during the past 12&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior treatment with Angiotensin-Receptor Blockers within two weeks from&#xD;
             first.&#xD;
&#xD;
          -  Severe or malignant hypertension (Systolic Blood Pressure / Diastolic Blood Pressure&#xD;
             greater than 180/110 mmHg).&#xD;
&#xD;
          -  Symptomatic hypotension.&#xD;
&#xD;
          -  Acute myocardial infarction within one month from first visit.&#xD;
&#xD;
          -  Stroke or transient ischemic attack within one month from first visit.&#xD;
&#xD;
          -  Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within&#xD;
             one month from first visit.&#xD;
&#xD;
          -  Hemodynamically relevant arrhythmias.&#xD;
&#xD;
          -  Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6&#xD;
             months prior the randomization.&#xD;
&#xD;
          -  Hemodynamically relevant cardiac valvular defect.&#xD;
&#xD;
          -  Constrictive pericarditis or active myocarditis.&#xD;
&#xD;
          -  Likelihood of cardiac surgical intervention (of any type) during the overall treatment&#xD;
             period.&#xD;
&#xD;
          -  Evidence of angina pectoris in the previous month.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated&#xD;
             hemoglobin greater than 8% obtained within three months from the study initiation).&#xD;
&#xD;
          -  Untreated thyroid dysfunction.&#xD;
&#xD;
          -  Renal artery stenosis.&#xD;
&#xD;
          -  Angioedema of any etiology.&#xD;
&#xD;
          -  Significant liver (aspartate aminotransferase, alanine aminotransferase, total&#xD;
             bilirubin or alkaline phosphatase greater than twice the upper limit of normal range)&#xD;
             or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0&#xD;
             mmol/L) impairment.&#xD;
&#xD;
          -  Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other&#xD;
             clinically relevant hematological disease.&#xD;
&#xD;
          -  Any disease with malabsorption.&#xD;
&#xD;
          -  Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly&#xD;
             (i.e. below 1 year from randomization) shorten life expectancy.&#xD;
&#xD;
          -  History of chronic alcohol or drug/substance abuse, or presence of other conditions&#xD;
             potentially able to affect study subjects' compliance.&#xD;
&#xD;
          -  Known allergy, sensitivity or intolerance to study drugs and/or study drugs'&#xD;
             formulation ingredients.&#xD;
&#xD;
          -  Participation in another trial in the month preceding study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Italia Farmaceutici SpA</affiliation>
  </overall_official>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Italia Farmaceutici SpA</organization>
  </responsible_party>
  <keyword>Natriuretic Peptide, Brain</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Cardiac Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Heart Decompensation</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

